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Summary 
The Centers for Disease Control and Prevention (CDC) is providing: 1) background information on the 
forms of e-cigarette products, 2) information on the multistate outbreak of severe pulmonary disease 
associated with using e-cigarette products (devices, liquids, refill pods, and cartridges), and 3) clinical 
features of patients with severe pulmonary disease. This health advisory also provides recommendations 
for clinicians, public health officials, and the public based on currently available information. 
 
General Background  
E-cigarettes typically contain nicotine, most also contain flavorings and other chemicals, and some may 
contain marijuana or other substances. They are known by many different names and come in many 
shapes, sizes and device types. Devices may be referred to as “e-cigs,” “vapes,” “e-hookahs,” “vape 
pens,” “mods,” tanks, or electronic nicotine delivery systems (ENDS). Some e-cigarette devices resemble 
other tobacco products such as cigarettes; some resemble ordinary household items such as USB flash 
drives, pens, and flashlights; and others have unique shapes. Use of e-cigarettes is sometimes referred 
to as “vaping” or “juuling.” E-cigarettes used for dabbing are sometimes called “dab” pens.  
 
E-cigarettes can contain harmful or potentially harmful substances, including nicotine, heavy metals (e.g., 
lead), volatile organic compounds, and cancer-causing chemicals. Additionally, some e-cigarette products 
are used to deliver illicit substances; may be acquired from unknown or unauthorized (i.e., “street”) 
sources; and may be modified for uses that could increase their potential for harm to the user. For 
example, some e-cigarette pods or cartridges marketed for single use can be refilled with illicit or 
unknown substances. In addition, some e-cigarette products are used for “dripping” or “dabbing.” Dripping 
involves dropping e-cigarette liquid directly onto the hot coils of an e-cigarette which can result in high 
concentrations of compounds (e.g., tetrahydrocannabinol [THC] and cannabinoid compounds). Dabbing 
involves superheating substances such as “budder”, butane hash oil (BHO), and “710” that contain high 
concentrations of THC and other plant compounds (e.g., cannabidiol [CBD]).  
Youth, young adults, pregnant women, as well as adults who do not currently use tobacco products 
should not use e-cigarettes. E-cigarettes containing nicotine have the potential to help some individual 
adult smokers reduce their use of and transition away from cigarettes. However, e-cigarettes are not 
currently approved by the Food and Drug Administration (FDA) as a quit smoking aid, and the available 
science is inconclusive on whether e-cigarettes are effective for quitting smoking.   
Outbreak Background 
As of August 27, 2019, 215 possible cases have been reported from 25 states and additional reports of 
pulmonary illness are under investigation. One patient (in Illinois) with a history of recent e-cigarette use 
was hospitalized on July 29, 2019 with severe pulmonary disease and died on August 20, 2019. Although 
the etiology of e-cigarette-associated pulmonary disease is undetermined, epidemiologic investigations in 
affected states are ongoing to better characterize the exposures, demographic, clinical, and laboratory 
features and behaviors of patients. All patients have reported using e-cigarette products. The exact 
number is currently unknown, but many patients have reported using e-cigarettes containing cannabinoid 
products such as THC or CBD.   
  
Based on reports from several states, patients have experienced respiratory symptoms (cough, shortness 
of breath, or chest pain), and some have also experienced gastrointestinal symptoms (nausea, vomiting, 
or diarrhea) or non-specific constitutional symptoms (fatigue, fever, or weight loss). Symptoms typically 
develop over a period of days but sometimes can manifest over several weeks. Gastrointestinal 
symptoms sometimes preceded respiratory symptoms. Fever, tachycardia, and elevated white blood cell 
count have been reported in the absence of an identifiable infectious disease. Many patients have sought 
initial care in ambulatory settings, some with several visits, before hospital admission.  
 
Radiologic findings have varied and are not present in all patients upon initial presentation. Bilateral 
pulmonary infiltrates and diffuse ground-glass opacities have been reported. Many patients required 
supplemental oxygen, some required assisted ventilation and oxygenation, and some were intubated. 
Some patients have been treated with corticosteroids with demonstrated improvement. Antimicrobial 
therapy alone has not consistently been associated with clinical improvement. Assessment for infectious 
etiologies has been completed in many patients without an identified infectious cause. Several patients 
from one state have been diagnosed with lipoid pneumonia based on clinical presentation and detection 
of lipids within bronchoalveolar lavage samples stained specifically to detect oil. 
 
All patients have reported using e-cigarette products and the symptom onset has ranged from a few days 
to several weeks after e-cigarette use.  Within two states, recent inhalation of cannabinoid products, THC 
or cannabidiol, have been reported in many of the patients. To date, no single substance or e-cigarette 
product has been consistently associated with illness. CDC is working closely with state health 
departments to facilitate collecting product specimens for testing at the U.S. FDA Forensic Chemistry 
Center.  
 
 
Recommendations for Clinicians 
1. Report cases of severe pulmonary disease of unclear etiology and a history of e-cigarette product use 
within the past 90 days to your state or local health department. Reporting of cases may help CDC 
and state health departments determine the cause or causes of these pulmonary illnesses.  
2. Ask all patients who report e-cigarette product use within the last 90 days about signs and symptoms 
of pulmonary illness. 
3. If e-cigarette product use is suspected as a possible etiology of a patient’s severe pulmonary disease, 
obtain detailed history regarding: 
• Substance(s) used: nicotine, cannabinoids (e.g., marijuana, THC, THC concentrates, CBD, 
CBD oil, synthetic cannabinoids [e.g., K2 or spice], hash oil, Dank vapes), flavors, or other 
substances 
• Substance source(s): commercially available liquids (i.e., bottles, cartridges, or pods), 
homemade liquids, and re-use of old cartridges or pods with homemade or commercially 
bought liquids 
• Device(s) used: manufacturer; brand name; product name; model; serial number of the 
product, device, or e-liquid; if the device can be customized by the user; and any product 
modifications by the user (e.g., exposure of the atomizer or heating coil) 
• Where the product(s) were purchased 
• Method of substance use: aerosolization, dabbing, or dripping  
• Other potential cases: sharing e-cigarette products (devices, liquids, refill pods, or cartridges) 
with others 
4. Determine if any remaining product, including devices and liquids, are available for testing. Testing 
can be coordinated with the local or state health departments. 
5. Consider all possible causes of illness in patients reporting respiratory and gastrointestinal symptoms 
and of e-cigarette product use. Evaluate and treat for other possible causes of illness (e.g., infectious, 
rheumatologic, neoplastic) as clinically indicated. Consider consultation with specialists (pulmonary, 
infectious disease, critical care, medical toxicology) as appropriate. 
6. Clinical improvement of patients with severe pulmonary disease associated with e-cigarette use has 
been reported with the use of corticosteroids. The decision to use corticosteroids should be made on 
a case-by-case basis based on risks and benefits and the likelihood of other etiologies.  
7. Lipoid pneumonia associated with inhalation of lipids in aerosols generated by e-cigarettes has been 
reported based on the detection of lipid-laden alveolar macrophages obtained by bronchoalveolar 
lavage (BAL) and lipid staining (e.g., oil red O). The decision about whether to perform a BAL should 
be based on individual clinical circumstances. 
8. Lung biopsies have been performed on some patients. If a lung biopsy is obtained, lipid staining may 
be considered during pathologic examination, and is best performed on fresh tissue. Routine 
pathology tissue processing (including formalin-fixation and paraffin-embedding) can remove lipids. 
Conducting routine tissue processing and histopathologic evaluation is still important. Consider 
consultation with specialists in pulmonary medicine and pathology to help inform any evaluation plan.  
9. Patients who have received treatment for severe pulmonary disease related to e-cigarette product 
use should undergo follow-up evaluation as clinically indicated to monitor pulmonary function. 
Recommendations for Public Health Officials 
1. State public health officials should promptly notify CDC about possible cases via 
VapingAssocIllness@cdc.gov.  
2. Contact CDC at VapingAssocIllness@cdc.gov for case classification criteria, reporting guidelines, 
case investigation forms, and questions about this outbreak.  
3. Consider conducting case-finding activities that use existing data sources (e.g., local poison control 
center, coroner and medical examiner’s office, and other applicable surveillance systems including 
syndromic surveillance). CDC has developed two working syndromic surveillance definitions (one 
version with specific symptoms and a second focused on e-cigarette product use). CDC will be 
programming these definitions in CDC’s National Syndromic Surveillance Program’s 
BioSense/ESSENCE platform for case-finding within the platform.  
4. Consider asking the medical examiner or coroner’s office and other pathologists to report possible 
cases, especially those without an alternative, likely diagnosis. If individuals are identified after death 
or at autopsy who showed signs of severe pulmonary disease as described above, medical 
examiners and coroners are encouraged to report the cases to their local or state health department. 
Thorough sampling of trachea, bronchi, and lung parenchyma with collection of fresh lung tissue for 
staining of lipids (e.g., oil red O) and submission of formalin-fixed, paraffin-embedded tissues for 
routine histopathology are recommended. For further consultation, public health officials can contact 
CDC’s Infectious Diseases Pathology Branch at pathology@cdc.gov.  
5. State health department officials seeking technical assistance with an epidemiologic investigation can 
contact CDC at VapingAssocIllness@cdc.gov. State health department officials seeking technical 
assistance with laboratory testing can discuss with their state health department laboratories or 
contact CDC at VapingAssocIllness@cdc.gov. 
Recommendations for the Public 
1. While this investigation is ongoing, if you are concerned about these specific health risks, consider 
refraining from using e-cigarette products.  
2. Regardless of the ongoing investigation, anyone who uses e-cigarette products should not buy these 
products off the street (e.g., e-cigarette products with THC, other cannabinoids) and should not 
modify e-cigarette products or add any substances to these products that are not intended by the 
manufacturer.  
3. Regardless of the ongoing investigation, e-cigarette products should not be used by youth, young 
adults, pregnant women, as well as adults who do not currently use tobacco products. If you use e-
cigarette products, monitor yourself for symptoms (e.g., cough, shortness of breath, chest pain) and 
promptly seek medical attention if you have concerns about your health. CDC and FDA will continue 
to advise and alert the public as more information becomes available.  
4. Adult smokers who are attempting to quit should use evidence-based treatments, including 
counseling and FDA-approved medications. If you who need help quitting tobacco products, including 
e-cigarettes, contact your doctor.  
5. If you are concerned about harmful effects from e-cigarette products, call your local poison control 
center at: 1-800-222-1222. 
6. We encourage the public to submit detailed reports of any unexpected tobacco or e-cigarette-related 
health or product issues to the FDA via the online Safety Reporting Portal: 
https://www.safetyreporting.hhs.gov.  
For More Information  
• For assistance with managing patients suspected of illness related to recreational, illicit, or other 
drugs, call your local poison control center at: 1-800-222-1222. 
• Information on electronic cigarettes and similar devices: https://www.cdc.gov/e-cigarettes      
• CDC Press Statement: https://www.cdc.gov/media/releases/2019/s0821-cdc-fda-states-e-
cigarettes.html   
• CDC Clinical Outreach and Communication Activity announcement: 
https://emergency.cdc.gov/newsletters/coca/081619.htm  
• CDC’s National Syndromic Surveillance Program’s BioSense/ESSENCE: 
https://www.cdc.gov/nssp/index.html  
• For more information, visit CDC Info: https://www.cdc.gov/cdc-info/index.html 
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The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing 
and controlling diseases and injuries; enhances health decisions by providing credible information on 
critical health issues; and promotes healthy living through strong partnerships with local, national, and 
international organizations. 
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Categories of Health Alert Network messages:  
 
Health Alert   Requires immediate action or attention; highest level of importance 
Health Advisory May not require immediate action; provides important information for a specific 
incident or situation 
Health Update   Unlikely to require immediate action; provides updated information regarding an 
incident or situation 
HAN Info Service Does not require immediate action; provides general public health information 
  
##This message was distributed to state and local health officers, state and local epidemiologists, state 
and local laboratory directors, public information officers, HAN coordinators, and clinician organizations## 
 
 
 
 
